** Shares of drug developer Septerna SEPN.O rise 1.8% to $10.66
** Brokerage H.C. Wainwright initiates coverage with "buy" rating, sets PT at $26
** SEPN's thyroid-stimulating hormone receptor $(TSHR)$ NAM candidate and potential lead candidate in parathyroid hormone 1 receptor program could each constitute future blockbusters in niche specialty indications that provide strategic optionality - brokerage
** Novo Nordisk NOVOb.CO in May struck a $2.2 billion collaboration and licensing deal with SEPN to develop oral small molecule medicines for obesity, type 2 diabetes and other cardio-metabolic diseases
** Brokerage believes the structure of the partnership provides significant strategic flexibility to SEPN, while eliminating clinical development and commercialization-related risk
** SEPN may have sufficient resources to fund operations beyond 2028, as Novo is committed to funding development of obesity and cardiometabolic disease-targeted candidates - Wainwright
** Up to last close, stock down 54.3% YTD
(Reporting by Juby Babu in Mexico City)
((Juby.Babu@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.